BMXMF OTC
bioMérieux S.A.
1W: +2.1%
1M: -2.2%
3M: +9.1%
YTD: -34.2%
1Y: -37.0%
3Y: -9.9%
5Y: -29.9%
$85.00
-0.31 (-0.36%)
Weekly Expected Move ±4.2%
$78
$81
$85
$89
$92
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$4.1B
+2.2% ▲
5Y CAGR: +5.5%
Gross Profit
$2.1B
-3.3% ▼
5Y CAGR: +4.1%
Operating Income
$561M
-4.7% ▼
5Y CAGR: +0.3%
Net Income
$397M
-8.1% ▼
5Y CAGR: -0.4%
EPS (Diluted)
$3.34
-8.2% ▼
5Y CAGR: -0.4%
EBITDA
$999M
+11.3% ▲
5Y CAGR: +4.6%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.4B | $3.6B | $3.7B | $4.0B | $4.1B |
| YoY Growth | +8.3% | +6.3% | +2.4% | +8.3% | +2.2% |
| Cost of Revenue | $1.4B | $1.6B | $1.6B | $1.8B | $1.9B |
| Gross Profit | $2.0B | $2.0B | $2.1B | $2.2B | $2.1B |
| Gross Margin | 59.3% | 56.0% | 56.0% | 55.7% | 52.6% |
| R&D Expenses | $389M | $447M | $540M | $492M | $507M |
| SG&A Expenses | $818M | $955M | $1.0B | $1.1B | $1.1B |
| Operating Expenses | $1.2B | $1.4B | $1.6B | $1.6B | $1.6B |
| Operating Income | $784M | $587M | $439M | $589M | $561M |
| Operating Margin | 23.2% | 16.4% | 11.9% | 14.8% | 13.8% |
| Interest Expense | $9M | $4M | $4M | $17M | $0 |
| Income Before Tax | $774M | $580M | $437M | $579M | $525M |
| Tax Expense | $176M | $140M | $114M | $154M | $129M |
| Net Income | $601M | $452M | $358M | $432M | $397M |
| Net Margin | 17.8% | 12.6% | 9.7% | 10.9% | 9.8% |
| EPS (Diluted) | $5.06 | $3.82 | $3.01 | $3.64 | $3.34 |
| EBITDA | $1.0B | $853M | $858M | $898M | $999M |
| Shares Outstanding | 119M | 118M | 119M | 119M | 119M |